All News
Filter News
Found 265 articles
-
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
-
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
8/11/2022
KemPharm, Inc. reported its financial results for the second quarter ended June 30, 2022.
-
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
8/9/2022
KemPharm, Inc. today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications.
-
KemPharm to Report Second Quarter 2022 Financial Results
8/4/2022
KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 11, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the second quarter 2022.
-
KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference
8/2/2022
KemPharm, Inc. today announced that Richard W. Pascoe, Executive Chairman of KemPharm, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
-
Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
8/2/2022
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent developments in its business.
-
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
7/26/2022
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced that members of the KemPharm team will attend the upcoming Niemann Pick Disease Foundation’s Family Support and Medical Conference.
-
Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
6/8/2022
Orphazyme A/S, reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
-
Orphazyme Announces Publication of 2021 Financial Results and Annual Report
6/7/2022
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.
-
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion
6/1/2022
KemPharm, Inc. announced that a manuscript summarizing the results of three clinical studies involving serdexmethylphenidate, KemPharm’s prodrug of dexmethylphenidate, was published in the peer-reviewed journal, Current Medical Research & Opinion.
-
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
5/31/2022
Following completion of the Sale of Assets to KemPharm, Orphazyme will no longer have any material ongoing operational business activities and KemPharm will retain all of Orphazyme’s remaining Danish employees, to continue the early access programs with arimoclomol, and to continue to pursue the potential approval of arimoclomol as a treatment option for NPC.
-
Restructuring proposal adopted by creditors
5/30/2022
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, announces that an in-court meeting was held where the restructuring proposal as published by the Company through company announcement no. 26/2022 on May 18, 2022, was approved by the Company’s creditors and affirmed by the Danish Maritime and Commercial High Court in accordance with sections 13 d and 13 e of the Danish Insolvency Act.
-
Changes to the Board of Directors - May 23, 2022
5/23/2022
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company, has previously announced its entry into an agreement with KemPharm Denmark A/S to sell substantially all of its assets and business activities and submission of the restructuring proposal to the Danish Maritime and Commercial High Court and the Company’s known creditors.
-
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
5/17/2022
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (“KemPharm”).
-
Orphazyme has several products with potential, with biopharma company KemPharm acquiring nearly all of the company's assets and operations.
-
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
5/16/2022
KemPharm, Inc. announced a definitive agreement with Orphazyme A/S to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein amplifier being developed as a treatment for Niemann-Pick disease type C.
-
Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
5/15/2022
Orphazyme A/S in restructuring, a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C, announces that it has signed an agreement to sell substantially all of the Company’s assets and business activities to KemPharm Denmark A/S, a wholly owned subsidiary of KemPharm Inc.
-
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
5/12/2022
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system and neurodegenerative diseases, reported its financial results for the first quarter ended March 31, 2022.
-
KemPharm to Present at Multiple Upcoming Investor Conferences
5/11/2022
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that members of management will participate in three upcoming in-person investor conferences.
-
KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)
5/5/2022
KemPharm, Inc. today announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration.